Your browser doesn't support javascript.
loading
Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
Novoplansky, Ofra; Shnerb, Avital B; Marripati, Divyasree; Jagadeeshan, Sankar; Abu Shareb, Raghda; Conde-López, Cristina; Zorea, Jonathan; Prasad, Manu; Ben Lulu, Talal; Yegodayev, Ksenia M; Benafsha, Chen; Li, Yushi; Kong, Dexin; Kuo, Fengshen; Morris, Luc G T; Kurth, Ina; Hess, Jochen; Elkabets, Moshe.
Afiliación
  • Novoplansky O; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Shnerb AB; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Marripati D; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Jagadeeshan S; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Abu Shareb R; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Conde-López C; Division of Radiooncology-Radiobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Zorea J; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Prasad M; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Ben Lulu T; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Yegodayev KM; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Benafsha C; Department of Chemical Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Li Y; Department of Biochemistry, University of Oxford, Oxford, UK.
  • Kong D; School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin, China.
  • Kuo F; Immunogenomics and Precision Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Morris LGT; Immunogenomics and Precision Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kurth I; Division of Radiooncology-Radiobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hess J; Section Experimental and Translational Head and Neck Oncology, Department of Otolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Germany.
  • Elkabets M; Research Group Molecular Mechanisms of Head and Neck Tumors, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
Mol Oncol ; 17(12): 2618-2636, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37501404
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfatidilinositol 3-Quinasa / Neoplasias de Cabeza y Cuello Límite: Animals / Humans Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfatidilinositol 3-Quinasa / Neoplasias de Cabeza y Cuello Límite: Animals / Humans Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Estados Unidos